LM Economic Consortium
  • Certified Programs
  • For Employers
  • For Healthcare Providers
Menu
  • About
  •    The Why of the
       LMERC
  •    Who
  •    Advisory Board
  •    Staff
  • Benefits
  •    For Employers
  •    For Healthcare
       Providers
  •    For Individuals
  • Resources
    • Key Papers and Presentations
    • Certified Programs
Consulting Evidence Database Download Database
Home » Evidences » Interventions with Positive Financial Outcomes » Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services.

Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services.

Submitted by admin on Tue, 08/21/2018 - 17:39

Author(s):

Bertram, M. Y., et al.

Year Published:

2018

Journal:

Lancet

Categories:

Interventions with Positive Financial Outcomes , Cardiovascular disease

Link to Abstract Summary:

https://www.ncbi.nlm.nih.gov/pubmed/29627159

Abstract:

The global burden of non-communicable diseases (NCDs) is growing, and there is an urgent need to estimate the costs and benefits of an investment strategy to prevent and control NCDs. Results from an investment-case analysis can provide important new evidence to inform decision making by governments and donors. We propose a methodology for calculating the economic benefits of investing in NCDs during the Sustainable Development Goals (SDGs) era, and we applied this methodology to cardiovascular disease prevention in 20 countries with the highest NCD burden. For a limited set of prevention interventions, we estimated that US$120 billion must be invested in these countries between 2015 and 2030. This investment represents an additional $1.50 per capita per year and would avert 15 million deaths, 8 million incidents of ischaemic heart disease, and 13 million incidents of stroke in the 20 countries. Benefit-cost ratios varied between interventions and country-income levels, with an average ratio of 5.6 for economic returns but a ratio of 10.9 if social returns are included. Investing in cardiovascular disease prevention is integral to achieving SDG target 3.4 (reducing premature mortality from NCDs by a third) and to progress towards SDG target 3.8 (the realisation of universal health coverage). Many countries have implemented cost-effective interventions at low levels, so the potential to achieve these targets and strengthen national income by scaling up these interventions is enormous.

Need the password to download the full database of studies?

Join our mailing list to get access to this as well as other key resources demonstrating the financial benefits of lifestyle medicine and health improvements:

Employers/Professionals Click Here

Healthcare Providers Click Here

Search and Filter

Press crtl for multiple selections
Range Between Start Year and End Year

We can help to reverse the trend, with the savings going right to your bottom line.

The solvency of our nation is at stake.

Benefits Evidence Database Consulting Resources Contact

Lifestyle Medicine Economic Research Council

The LMERC is a special project of the American College of Lifestyle Medicine, a 501(c)3 non-profit charitable organization dedicated to advancing the field of lifestyle medicine as the foundation of a transformed and sustainable system of healthcare delivery.

facebook Twitter Contact
LM Economic Consortium
© 2022 American College of Lifestyle Medicine. Site By Fusion Media Marketing